2024
Longer Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease
McMillan C, Li D, Mohamed G, Alsadoun D, Almohsen L, Gaidos J, Proctor D, Al-Bawardy B. Longer Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2024, 6: otae020. PMID: 38585555, PMCID: PMC10998460, DOI: 10.1093/crocol/otae020.Peer-Reviewed Original ResearchColonoscopy withdrawal timeHigh-definition white light colonoscopyInflammatory bowel diseaseWhite light colonoscopyVisible dysplasiaBowel diseasePersonal historyWithdrawal timeAssociated with detectionEndoscopic healingAdenoma detectionDysplasia detectionDysplasia groupRetrospective studyAdult patientsInvisible dysplasiaColonoscopyPrimary outcomeDysplasiaMultivariate analysisPatientsIncreasing ageGeneral populationMinutesDisease
2023
Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy.
Azzam N, Almutairdi A, Almudaiheem H, AlAmeel T, Bakkari S, Alharbi O, Alenzi K, AlMolaiki M, Al-Omari B, Albarakati R, Al-Jedai A, Saadah O, Almadi M, Al-Bawardy B, Mosli M. Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy. Saudi Journal Of Gastroenterology 2023, 30 PMID: 38099556, PMCID: PMC11379253, DOI: 10.4103/sjg.sjg_318_23.Peer-Reviewed Original ResearchInflammatory bowel diseaseManagement of IBDPregnant womenBowel diseaseClear evidence-based recommendationsSubset of patientsClinical care pathwayExpert opinion recommendationsOptimal patient managementEvidence-based recommendationsMultidisciplinary working groupCare pathwayClinical pharmacologyPatient managementPatient basisConsensus guidanceMultidisciplinary teamSaudi MinistryWomenPatientsDiseaseConcise guidelinesWorking GroupLiterature reviewManagementTherapeutic drug monitoring of ustekinumab and vedolizumab in inflammatory bowel disease: worth the draw?
Chaar A, Atiyat R, Al-Bawardy B. Therapeutic drug monitoring of ustekinumab and vedolizumab in inflammatory bowel disease: worth the draw? Digestive Medicine Research 2023, 0: 0-0. DOI: 10.21037/dmr-22-80.Peer-Reviewed Original Research
2022
Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease
Mosli M, Almudaiheem H, AlAmeel T, Bakkari S, Alharbi O, Alenzi K, Khardaly A, AlMolaiki M, Al-Omari B, Albarakati R, Al-Jedai A, Saadah O, Almadi M, Al-Bawardy B. Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease. Saudi Journal Of Gastroenterology 2022, 29: s1-s35. PMID: 36412460, PMCID: PMC10540981, DOI: 10.4103/sjg.sjg_277_22.Peer-Reviewed Original ResearchInflammatory bowel diseaseBowel diseaseManagement of IBDExpert opinion-based recommendationsManagement of adultsOpinion-based recommendationsLevel of evidenceEvidence-based interventionsIBD diagnosisUlcerative colitisCrohn's diseaseConsensus guidelinesConsensus guidanceOptimal managementClinical pharmacyDiseaseSaudi MinistryAdultsDiagnosisConcise guidelinesGuidelinesLiterature reviewTime of writingColitisPatients
2021
Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
Ramos G, Al-Bawardy B, Neto M, Bledsoe A, Quinn K, Heron V, Willrich M, Johnson A, Chedid V, Coelho-Prabhu N, Kisiel J, Papadakis K, Pardi D, Kane S, Tremaine W, Raffals L, Bruining D, Faubion W, Harmsen W, Loftus E. Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Crohn's & Colitis 360 2021, 3: otab019. PMID: 36776673, PMCID: PMC9802288, DOI: 10.1093/crocol/otab019.Peer-Reviewed Original ResearchRadiologic responseClinical responseCertolizumab pegolMucosal healingCrohn's diseaseRadiologic healingCD patientsTrough levelsPositive antibody levelsSingle-center experienceCD outcomesAntibody levelsClinical managementOdds ratioCTL levelsHigher oddsRetrospective evaluationPatientsBiochemical responsesClinical practiceQuartile analysisAntibodiesCharacteristic curveOutcomesDiseaseNovel and Emerging Therapies for Inflammatory Bowel Disease
Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Frontiers In Pharmacology 2021, 12: 651415. PMID: 33935763, PMCID: PMC8080036, DOI: 10.3389/fphar.2021.651415.BooksInflammatory bowel diseaseBowel diseaseAnti-tumor necrosis factorPotential systemic manifestationsSecondary treatment failureTreatment response ratesJanus kinase inhibitorSelective Janus kinase inhibitorNew therapeutic targetsEmerging TherapiesCurrent biologicsIntestinal inflammationSystemic manifestationsUlcerative colitisCrohn's diseaseTreatment failureSafety profileNecrosis factorTherapeutic targetResponse rateDiseaseKinase inhibitorsTarget agentsInhibitorsTolerability
2019
Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease
Park S, Al-Bawardy B, Aniwan S, Kane S, Coelho-Prabhu N, Papadakis K, Kisiel J, Bruining D, Faubion W, Raffals L, Pardi D, Tremaine W, Stephens M, Tung J, Khanna S, Willrich M, Loftus E. Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2019, 1: otz047. DOI: 10.1093/crocol/otz047.Peer-Reviewed Original ResearchAdalimumab trough levelsRadiologic responseDisease activityTrough levelsReferral center-based cohortInflammatory bowel disease patientsRadiologic disease activityBowel disease patientsInflammatory bowel diseaseC-reactive proteinDifferent therapeutic outcomesHigher cutoff levelsBowel diseaseDisease patientsCutoff levelTherapeutic outcomesCutoff valuePatientsCohortIBDLevelsDiseaseResponse
2017
Endoscopic and Radiographic Assessment of Crohn's Disease
Al-Bawardy B, Hansel SL, Fidler JL, Barlow JM, Bruining DH. Endoscopic and Radiographic Assessment of Crohn's Disease. Gastroenterology Clinics Of North America 2017, 46: 493-513. PMID: 28838411, DOI: 10.1016/j.gtc.2017.05.005.BooksConceptsCrohn's diseaseFavorable long-term outcomeEndoscopic mucosal healingRadiologic scoring systemChronic inflammatory disordersLong-term outcomesObjective measuresRadiologic responseDisease activityClinical improvementMucosal healingClinical symptomsReduced hospitalizationsInflammatory disordersRadiographic assessmentTreatment targetsScoring systemScoring toolDiseaseMore objective measuresTherapyCorticosteroidsHospitalizationComplicationsInflammationBeyond moulage sign and TTG levels: the role of cross-sectional imaging in celiac sprue
Sheedy SP, Barlow JM, Fletcher JG, Smyrk TC, Scholz FJ, Codipilly DC, Al Bawardy BF, Fidler JL. Beyond moulage sign and TTG levels: the role of cross-sectional imaging in celiac sprue. Abdominal Radiology 2017, 42: 361-388. PMID: 28154909, DOI: 10.1007/s00261-016-1006-2.BooksConceptsCeliac diseaseMesenteric lymph node syndromeCross-sectional imaging findingsComplicated celiac diseaseRefractory celiac diseaseLymph node syndromeEarly treatment initiationIngestion of glutenT-cell lymphomaCross-sectional imagingMalabsorptive processesAtypical presentationTreatment initiationImaging findingsSignificant morbidityAutoimmune disordersCeliac sprueEndoscopic investigationTTG levelsCell lymphomaSusceptible individualsSmall intestineGreater riskDiseaseComplimentary modalities
2011
Women with Inflammatory Bowel Disease Do Not Receive Adequate Cervical Cancer Screening or Pregnancy Counseling
Greywoode R, LaFond J, Fine S, Al-Bawardy B, Jencks D, Shafa S, Borum ML. Women with Inflammatory Bowel Disease Do Not Receive Adequate Cervical Cancer Screening or Pregnancy Counseling. Inflammatory Bowel Diseases 2011, 19: e6-e7. PMID: 22109963, DOI: 10.1002/ibd.22836.Peer-Reviewed Original Research